ACADIA Pharmaceuticals Inc. (ACAD) Earns Buy Rating from Jefferies Group LLC
Jefferies Group LLC reaffirmed their buy rating on shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) in a report issued on Thursday morning. They currently have a $47.00 price objective on the biopharmaceutical company’s stock.
ACAD has been the subject of a number of other reports. Zacks Investment Research lowered shares of ACADIA Pharmaceuticals from a buy rating to a sell rating in a report on Monday, July 17th. Ladenburg Thalmann Financial Services reaffirmed a buy rating and set a $50.00 price target (up from $48.00) on shares of ACADIA Pharmaceuticals in a report on Monday, October 2nd. Goldman Sachs Group, Inc. (The) reaffirmed a neutral rating and set a $45.00 price target on shares of ACADIA Pharmaceuticals in a report on Friday, October 6th. BidaskClub raised shares of ACADIA Pharmaceuticals from a sell rating to a hold rating in a report on Monday, July 24th. Finally, Leerink Swann reaffirmed a market perform rating on shares of ACADIA Pharmaceuticals in a report on Monday, October 9th. Six investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $46.21.
ACADIA Pharmaceuticals (NASDAQ ACAD) traded down 0.28% during trading on Thursday, hitting $35.40. 1,368,558 shares of the company’s stock traded hands. ACADIA Pharmaceuticals has a 12-month low of $20.68 and a 12-month high of $41.20. The firm’s 50-day moving average price is $36.78 and its 200 day moving average price is $31.70. The stock’s market cap is $4.33 billion.
ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.72) by $0.17. The business had revenue of $30.50 million during the quarter, compared to analyst estimates of $20.02 million. ACADIA Pharmaceuticals had a negative net margin of 485.14% and a negative return on equity of 62.08%. The business’s revenue was up 30400.0% on a year-over-year basis. During the same period last year, the business earned ($0.63) EPS. Analysts anticipate that ACADIA Pharmaceuticals will post ($2.55) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This report was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.watchlistnews.com/acadia-pharmaceuticals-inc-acad-earns-buy-rating-from-jefferies-group-llc/1632645.html.
In other ACADIA Pharmaceuticals news, EVP Glenn Baity sold 14,322 shares of the firm’s stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $34.88, for a total transaction of $499,551.36. Following the completion of the transaction, the executive vice president now directly owns 78,578 shares of the company’s stock, valued at approximately $2,740,800.64. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last three months, insiders have sold 116,426 shares of company stock valued at $4,100,885. 22.25% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of ACAD. Envestnet Asset Management Inc. boosted its holdings in shares of ACADIA Pharmaceuticals by 23.0% in the 1st quarter. Envestnet Asset Management Inc. now owns 3,296 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 617 shares during the period. San Francisco Sentry Investment Group CA acquired a new position in shares of ACADIA Pharmaceuticals in the 2nd quarter valued at about $125,000. Oppenheimer Asset Management Inc. boosted its holdings in shares of ACADIA Pharmaceuticals by 10.0% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 5,133 shares of the biopharmaceutical company’s stock valued at $143,000 after buying an additional 468 shares during the period. PNC Financial Services Group Inc. boosted its holdings in shares of ACADIA Pharmaceuticals by 138.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 4,384 shares of the biopharmaceutical company’s stock valued at $150,000 after buying an additional 2,548 shares during the period. Finally, Flagship Harbor Advisors LLC acquired a new position in shares of ACADIA Pharmaceuticals in the 1st quarter valued at about $202,000. 97.10% of the stock is owned by institutional investors and hedge funds.
ACADIA Pharmaceuticals Company Profile
ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).
Receive News & Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.